UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Bupivacaine Extended-Release Liposome Injection for Prolonged Postsurgical Analgesia in Patients Undergoing Hemorrhoidectomy: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Diseases of the colon & rectum, 2011-12, Vol.54 (12), p.1552-1559

2011

Volltextzugriff (PDF)

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

Blood, 2019-02, Vol.133 (9), p.893-901

2019

Volltextzugriff (PDF)

PB2299: UPDATE ON TRIAL IN PROGRESS: A PHASE 1B STUDY OF ELA026 IN PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (SHLH)

HemaSphere, 2023-08, Vol.7 (S3), p.e7332173-n/a

2023

Volltextzugriff (PDF)

In vogue with venture

Nature biotechnology, 2011-11, Vol.29 (11), p.967-969

Patou, Gary

2011

Volltextzugriff (PDF)

In vogue with venture: what types of life science enterprises are attracting venture capitalists today?

Nature biotechnology, 2011-11, Vol.29 (11), p.967

Patou, Gary

2011

Volltextzugriff (PDF)

Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting

Current medical research and opinion, 2012-10, Vol.28 (10), p.1609-1615

2012

Volltextzugriff (PDF)

Trial in Progress: A Phase 1b Study of ELA026 in Patients with Secondary Hemophagocytic Lymphohistiocytosis

Blood, 2022-11, Vol.140 (Supplement 1), p.8336-8337

2022

Volltextzugriff (PDF)

Pharmacokinetics in Animals and Humans of a First-in-Class Peptide Deformylase Inhibitor

Antimicrobial Agents and Chemotherapy, 2004-12, Vol.48 (12), p.4835-4842

2004

Volltextzugriff (PDF)

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide

The journal of clinical endocrinology and metabolism, 2020-10, Vol.105 (10), p.e3785-e3797

2020

Volltextzugriff (PDF)

A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis

Blood, 2023-11, Vol.142 (Supplement 1), p.1162-1162

2023

Volltextzugriff (PDF)

Durable biochemical response and safety with oral octreotide capsules in acromegaly

European journal of endocrinology, 2022-12, Vol.187 (6), p.733-741

2022

Volltextzugriff (PDF)

Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia

Journal of Pain Research, 2012, Vol.5 (default), p.107-116

2012

Volltextzugriff (PDF)

Time to onset of analgesia following local infiltration of liposome bupivacaine in healthy volunteers: a randomized, single-blind, sequential cohort, crossover study

International journal of clinical pharmacology and therapeutics, 2013-05, Vol.51 (5), p.367-373

2013

Volltextzugriff (PDF)

Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial

The lancet. Diabetes & endocrinology, 2022-02, Vol.10 (2), p.102-111

2022

Volltextzugriff (PDF)

The safety of liposome bupivacaine following various routes of administration in animals

Journal of pain research, 2015-01, Vol.8 (default), p.781-789

2015

Volltextzugriff (PDF)

Abstract #1041607: Effects of Prior Injectable Somatostatin Receptor Ligand Type and Dose in Patients With Acromegaly Receiving Oral Octreotide Capsules in the Phase 3 MPOWERED Trial

Endocrine practice, 2021-06, Vol.27 (6), p.S131-S131

2021

Volltextzugriff (PDF)

Abstract #1000028: Injection Site Reactions and Their Impact in Patients With Acromegaly Receiving Injectable Somatostatin Receptor Ligands in the Phase 3 MPOWERED Trial

Endocrine practice, 2021-06, Vol.27 (6), p.S112-S113

2021

Volltextzugriff (PDF)

Abstract #1041639: Improved Quality of Life and Work Productivity in Patients With Acromegaly Receiving Oral Octreotide Capsules in the Phase 3 MPOWERED Trial

Endocrine practice, 2021-06, Vol.27 (6), p.S132-S132

2021

Volltextzugriff (PDF)

Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients

Blood, 2017-12, Vol.130 (Suppl_1), p.703-703

2017

Volltextzugriff (PDF)

Abstract #938: Mpowered: Study Design of a Phase 3 Head-To-Head Trial Evaluating Oral Octreotide Capsules Versus Injectable Somatostatin Analogs in Patients with Acromegaly

Endocrine practice, 2016-05, Vol.22, p.214-215

2016

Volltextzugriff (PDF)

MPOWERED: STUDY DESIGN OF A PHASE 3 HEAD-TO-HEAD TRIAL EVALUATING ORAL OCTREOTIDE CAPSULES VERSUS INJECTABLE SOMATOSTATIN ANALOGS IN PATIENTS WITH ACROMEGALY

Endocrine practice, 2016-05, Vol.22, p.214

2016

Volltextzugriff (PDF)

OR23-07 Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study of Oral Octreotide Capsules in Adult Patients with Acromegaly

Journal of the Endocrine Society, 2020-05, Vol.4 (Supplement_1)

2020

Volltextzugriff (PDF)

MON-LB55 Biochemical Control of Most Patients Reverting to Injectable Long-Acting Somatostatin Receptor Ligands Is Achieved After One Dose: Results From the Phase 3, Randomized, Double Blind, Placebo-Controlled Optimal Study

Journal of the Endocrine Society, 2020-05, Vol.4 (Supplement_1)

2020

Volltextzugriff (PDF)

One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly

Journal of the Endocrine Society, 2021-05, Vol.5 (Supplement_1), p.A515-A516

2021

Volltextzugriff (PDF)

MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study

Journal of the Endocrine Society, 2020-05, Vol.4 (Supplement_1)

2020

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(61)
Dissertationen
(1)

Sprache

Englisch
(62)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(17)
Science & Technology
(17)
Humans
(15)
Neuroendocrinology And Pituitary
(12)
Adult
(10)
Biological And Medical Sciences
(9)
Female
(9)
Male
(9)
Medical Sciences
(8)
Middle Aged
(7)
Infectious Diseases
(6)
Double-Blind Method
(5)
Liposomes
(5)
Aged
(4)
Anesthetics, Local - Administration & Dosage
(4)
Bupivacaine - Administration & Dosage
(4)
Immunology
(4)
Pain Measurement
(4)
Aids/hiv
(3)
Endocrinology & Metabolism
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bupivacaine Extended-Release Liposome Injection for Prolonged Postsurgical Analgesia in Patients Undergoing Hemorrhoidectomy: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

PB2299: UPDATE ON TRIAL IN PROGRESS: A PHASE 1B STUDY OF ELA026 IN PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (SHLH)

In vogue with venture

In vogue with venture: what types of life science enterprises are attracting venture capitalists today?

Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting

Trial in Progress: A Phase 1b Study of ELA026 in Patients with Secondary Hemophagocytic Lymphohistiocytosis

Pharmacokinetics in Animals and Humans of a First-in-Class Peptide Deformylase Inhibitor

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide

A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis

Durable biochemical response and safety with oral octreotide capsules in acromegaly

Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia

Time to onset of analgesia following local infiltration of liposome bupivacaine in healthy volunteers: a randomized, single-blind, sequential cohort, crossover study

Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial

The safety of liposome bupivacaine following various routes of administration in animals

Abstract #1041607: Effects of Prior Injectable Somatostatin Receptor Ligand Type and Dose in Patients With Acromegaly Receiving Oral Octreotide Capsules in the Phase 3 MPOWERED Trial

Abstract #1000028: Injection Site Reactions and Their Impact in Patients With Acromegaly Receiving Injectable Somatostatin Receptor Ligands in the Phase 3 MPOWERED Trial

Abstract #1041639: Improved Quality of Life and Work Productivity in Patients With Acromegaly Receiving Oral Octreotide Capsules in the Phase 3 MPOWERED Trial

Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients

Abstract #938: Mpowered: Study Design of a Phase 3 Head-To-Head Trial Evaluating Oral Octreotide Capsules Versus Injectable Somatostatin Analogs in Patients with Acromegaly

MPOWERED: STUDY DESIGN OF A PHASE 3 HEAD-TO-HEAD TRIAL EVALUATING ORAL OCTREOTIDE CAPSULES VERSUS INJECTABLE SOMATOSTATIN ANALOGS IN PATIENTS WITH ACROMEGALY

OR23-07 Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study of Oral Octreotide Capsules in Adult Patients with Acromegaly

MON-LB55 Biochemical Control of Most Patients Reverting to Injectable Long-Acting Somatostatin Receptor Ligands Is Achieved After One Dose: Results From the Phase 3, Randomized, Double Blind, Placebo-Controlled Optimal Study

One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly

MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study

Suchergebnisse filtern